Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
New study into pain associated with diabetes

New study into pain associated with diabetes

dSarm/Sarm1 gene promotes axon destruction after injury

dSarm/Sarm1 gene promotes axon destruction after injury

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Three-drug regimen provides rapid, durable responses for multiple myeloma

Three-drug regimen provides rapid, durable responses for multiple myeloma

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

NIH Consortium selects UBM among 11 CoEPEs

NIH Consortium selects UBM among 11 CoEPEs

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

Inform Genomics completes first phase in oral mucositis risk prediction study

Inform Genomics completes first phase in oral mucositis risk prediction study

FDA grants Fast Track designation to EpiCept's AmiKet

FDA grants Fast Track designation to EpiCept's AmiKet

Nerve pain patients in Wales gain access to first of a kind treatment which can provide lasting pain relief

Nerve pain patients in Wales gain access to first of a kind treatment which can provide lasting pain relief

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept fourth quarter revenue decreases to $0.2 million

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.